ACTG 315 Short-Term Viral Dynamic Data for NLME Model Fitting


1. The data were produced from AIDS Clinical Trials Group, ACTG 315 study, which is sponsored by NIAID/NIH. If you have any questions regarding the data, you may contact Dr. Hulin Wu by email, hwu@bst.rochester.edu.

2. The detailed biomedical findings from this study and more detailed description of the study design can be found from the primary and secondary publications of this study, Lederman et al (1998) and Connick et al. (2000) (see below for these references).

3. Some early viral dynamic modeling analyses based on this study are reported in the following papers:

4. This data set was slightly modified from the data used in Wu and Ding (1999, Biometrics). More data were added in the database. The data were re-cleaned after the analysis of Wu and Ding (1999). Only first 12-week data are included. The rebounded viral load data are deleted based on the description in Wu and Ding (1999).

5. Among total 53 patients accrued in this study, five patients dropped out before Week 12 due to intolerance and other problems. They are excluded from our analysis. Negative time (days) is the pre-entry measurements before antiviral treatment initiated.

6. Detection limit of the viral load (HIV RNA copies) assay is 100 copies per ml blood. If it is below detection, we imputed 100 in the data set although we imputed as 50 in our analysis (Wu and Ding 1999). If more than one measurement below detectable level for an individual, we just impute the first measurement and exclude the rest of them in our analysis (otherwise it may result in misleading dynamic patterns).

7. Fit the updated data using Wu and Ding (1999) method:


8. Please cite the following references if appropriate when you use the data in your paper:

1) Connick E, Lederman MM, Kotzin BL, et al. (2000), "Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response," Journal of Infectious Diseases, 181:358-63.

2) Ding, A.A. and Wu, H. (1999), "Relationships between Antiviral Treatment Effects and Biphasic Viral Decay Rates in Modeling HIV Dynamics," Mathematical Biosciences, 160. 63-82.

3) Ding, A.A. and Wu, H. (2000), "A Comparison Study of Models and Fitting Procedures for Biphasic Viral Dynamics in HIV-1 Infected Patients Treated with Antiviral Therapies," Biometrics, 56, 293-300.

4) Lederman MM, Connick E, Landay A, et al. (1998), "Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine and ritonavir: results of AIDS Clinical Trials Group Protocol 315," Journal of Infectious Diseases, 178: 70-79.

5) Wu, H. and Ding, A. (1999), "Population HIV-1 Dynamics in Vivo: Applicable Models and Inferential Tools for Virological Data from AIDS Clinical Trials," Biometrics, 55, 410-418.

6) Wu, H. and Ding, A. and DeGruttola. V. (1998), "Estimation of HIV Dynamic Parameters," Statistics in Medicine, 17, 2463-2485.

7) Wu, H., Kuritzkes, D.R., and McClernon, D.R. et al. (1999), "Characterization of Viral Dynamics in Human Immunodeficiency Virus Type 1-Infected Patients Treated with Combination Antiretroviral Therapy: Relationships to Host Factors, Cellular Restoration and Virological Endpoints," Journal of Infectious Diseases, 179(4):799-807.